Boehringer signs manufacturing agreement with MorphoSys
Covers process development and manufacturing of clinical material for MOR208 antibody
German pharmaceutical firm Boehringer Ingelheim has signed a biopharmaceutical manufacturing agreement for therapeutic antibodies with biotechnology firm MorphoSys, based in Munich.
The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's MOR208, a monoclonal anti-CD19 antibody for the treatment of chronic lymphocytic leukaemia and potentially other B-cell malignancies. MorphoSys's partner Xencor is currently evaluating MOR208 in a phase 1 clinical trial in the US.
Simon Sturge, corporate senior vice president of the biopharmaceuticals division at Boehringer Ingelheim, said the combination of MorphoSys's successful track record in the discovery and clinical development of antibody-based therapeutics and the company’s proven competence in technical development and manufacturing will be an optimal fit.
